Wockhardt Ltd News

Pharma stocks zoom: Laurus Labs, Aurobindo hit new highs in trade

The BSE Healthcare index rallied over 1% in Monday's trade. Thus far in the financial year 2026-27, it outperformed the market by soaring 25%, against a near 4% rise in the BSE Sensex.

Nifty tech outlook signals caution, says Angel One; shares two stock ideas

The emerging technical structure highlights the need to exercise caution and warrants a clear strategy to avoid venturing into aggressive long trades.

Wockhardt Q1 results: Revenue rises 26% to ₹929 cr, profit at ₹107 cr

Pharmaceuticals firm Wockhardt Ltd on Monday reported a consolidated profit after tax of Rs 107 crore for the first quarter ended June 30, mainly due to strong revenue growth. The company had posted a consolidated net loss of Rs 108 crore in the corresponding period of the last fiscal, Wockhardt Ltd said in a regulatory filing. Its consolidated revenue from operations in the first quarter stood at Rs 929 crore against Rs 738 crore a year ago, it added. Total expenses in the quarter under review were higher at Rs 844 crore compared to Rs 770 crore in the year-ago period, it said.

Nifty Pharma extends rally, up 2%; Piramal Pharma, Laurus gain up to 10%

Analysts said that a combination of defensive buying, strong earnings visibility, export tailwinds, and sector rotation is driving the rally in pharma stocks.

Beyond Zaynich: Wockhardt bets on WCK 6777 as next blockbuster jab

Once-a-day injectable antibiotic aimed at treatment beyond hospitals through outpatient centres

Wockhardt targets 50% of revenue from novel drugs within five years

Wockhardt expects novel drugs to contribute over half its revenue within five years as it expands a differentiated antibiotic portfolio built through decades of R&D

Wockhardt eyes $1.5 bn peak sales from Zaynich, targets US launch by yr-end

Novel antibiotic to be launched in India around the same time; company to commercialise product on its own in US

Wockhardt soars 19%, zooms 75% in 1 month; what's driving pharma stock?

Wockhardt recently received USFDA approval for Zaynich (cefepime and zidebactam), a novel intravenous antibiotic for treating complicated urinary tract infections, including pyelonephritis, in adults.

Wockhardt hits all-time high on CDSCO approval for antibiotic Zaynich

The buying on the counter came after the company received approval from the CDSCO for the import and marketing of Zaynich Zidebactam/Cefepime

Breakout stocks: How to trade Ola, GMR Airports, Wockhardt? Analyst decodes

Mayank Jain, market analyst at Share.Market by PhonePe believes that the long-term trend for Ola Electric can change from 'Bearish to Bullish' if the stock manages to sustain above ₹40 consistently.

Stocks to buy: Wockhardt, TFCI, HBL Engg among analyst's top bets; check TP

Kunal Kamble, sr. technical research analyst at Bonanza, has recommended buying shares of Wockhardt, TFCI, and HBL Engineering today